Reuters logo
BRIEF-XBIOTECH ‍ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE
2017年10月18日 / 下午3点00分 / 1 个月前

BRIEF-XBIOTECH ‍ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE

Oct 18 (Reuters) - Xbiotech Inc:

* ‍ENROLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN COMBINATION WITH ONIVYDE & 5-FLUOROURACIL/FOLINIC ACID FOR TREATMENT OF PANCREATIC CANCER​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below